HBV及其相关蛋白泛素化修饰研究进展

涂文辉; 刘锦; 朱传武

doi:10.3969/j.issn.1001-5256.2021.09.038

HBV及其相关蛋白泛素化修饰研究进展

DOI: 10.3969/j.issn.1001-5256.2021.09.038

涂文辉^{1, 2},
刘锦¹,
朱传武^1, ,

1.
苏州大学附属传染病医院，苏州市第五人民医院肝病科，江苏苏州 215131
2.
浙江省台州市立医院感染科, 浙江台州 318000

基金项目:

浙江省医药卫生科技计划项目 (2020KY368);

浙江省医药卫生科技计划项目 (2021KY1217);

苏州市姑苏卫生人才计划项目 (GSWS2020091)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：涂文辉、刘锦负责文献查找，资料分析，撰写论文；朱传武拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
朱传武，zhuchw@126.com

中图分类号: R512.62
计量
- 文章访问数: 337
- HTML全文浏览量: 196
- PDF下载量: 53
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-16
- 录用日期: 2021-02-23
- 出版日期: 2021-09-20

Research advances in hepatitis B virus and ubiquitination of related proteins

Wenhui TU^{1, 2},
Jin LIU¹,
Chuanwu ZHU^{1
, ,}

1.
Department of Hepatology, The Affiliated Infectious Diseases Hospital of Soochow University & The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu 215131, China
2.
Department of Infectious Diseases, Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, China

Research funding:

Projects of Medical and Health Technology in Zhejiang Province （2020KY368）

Projects of Medical and Health Technology in Zhejiang Province （2021KY1217）

Project of Gusu Health Talent Plan of Suzhou （GSWS2020091）

摘要

摘要: 蛋白质泛素化广泛存在于细胞内，是蛋白翻译后的一种修饰。HBV及其相关蛋白的泛素化研究越来越受到重视。对HBV及其相关蛋白的泛素化修饰进行了综述，为进一步了解HBV的复制调控及其蛋白的泛素化研究提供了借鉴，为治愈慢性HBV感染提供新的思路和方法。
- 乙型肝炎病毒 /
- 病毒蛋白质类 /
- 泛素化
Abstract: Protein ubiquitination is widely observed in cells and is a modification after protein translation. Hepatitis B virus (HBV) and ubiquitination of related proteins have attracted more and more attention. This article reviews HBV and the ubiquitination of related proteins, so as to provide a reference for further research on the regulation of HBV replication and the ubiquitination of related proteins, as well as new ideas and methods for curing chronic HBV infection.
- Hepatitis B Virus /
- Viral Proteins /
- Ubiquitination

HTML全文

图 1 E3泛素连接酶调节抗病毒天然免疫信号

下载: 全尺寸图片幻灯片

图 2 HBx介导的发病机制中与泛素蛋白酶体系统有关的情况

下载: 全尺寸图片幻灯片

图 3 泛素蛋白酶体系统在HBV复制中的调控机制

下载: 全尺寸图片幻灯片

参考文献(45)

[1]	TONG S, REVILL P. Overview of hepatitis B viral replication and genetic variability[J]. J Hepatol, 2016, 64(1 Suppl): s4-s16. DOI: 10.1016/j.jhep.2016.01.027.
[2]	HICKE L. Protein regulation by monoubiquitin[J]. Nat Rev Mol Cell Biol, 2001, 2(3): 195-201. DOI: 10.1038/35056583.
[3]	HERSHKO A, CIECHANOVER A. The ubiquitin system[J]. Annu Rev Biochem, 1998, 67: 425-479. DOI: 10.1146/annurev.biochem.67.1.425.
[4]	ZHENG Y, GAO C. Fine-tuning of antiviral innate immunity by ubiquitination[J]. Adv Immunol, 2020, 145: 95-128. DOI: 10.1016/bs.ai.2019.11.004.
[5]	TOH QC, TAN TL, TEO WQ, et al. Identification of cellular membrane proteins interacting with hepatitis B surface antigen using yeast split-ubiquitin system[J]. Int J Med Sci, 2005, 2(3): 114-117. DOI: 10.7150/ijms.2.114.
[6]	HARTMANN-STVHLER C, PRANGE R. Hepatitis B virus large envelope protein interacts with gamma2-adaptin, a clathrin adaptor-related protein[J]. J Virol, 2001, 75(11): 5343-5351. DOI: 10.1128/JVI.75.11.5343-5351.2001.
[7]	MANGOLD CM, STREECK RE. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein[J]. J Virol, 1993, 67(8): 4588-4597. DOI: 10.1128/JVI.67.8.4588-4597.1993.
[8]	LIU Y, TESTA JS, PHILIP R, et al. A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation[J]. PLoS One, 2011, 6(9): e24477. DOI: 10.1371/journal.pone.0024477.
[9]	SIMSEK E, MEHTA A, ZHOU T, et al. Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme[J]. J Virol, 2005, 79(20): 12914-12920. DOI: 10.1128/JVI.79.20.12914-12920.2005.
[10]	ROST M, MANN S, LAMBERT C, et al. Gamma-adaptin, a novel ubiquitin-interacting adaptor, and Nedd4 ubiquitin ligase control hepatitis B virus maturation[J]. J Biol Chem, 2006, 281(39): 29297-29308. DOI: 10.1074/jbc.M603517200.
[11]	GARCIA ML, BYFIELD R, ROBEK MD. Hepatitis B virus replication and release are independent of core lysine ubiquitination[J]. J Virol, 2009, 83(10): 4923-4933. DOI: 10.1128/JVI.02644-08.
[12]	LANGEROVÁ H, LUBYOVÁ B, ZÁBRANSKÝ A, et al. Hepatitis B core protein is post-translationally modified through K29-linked ubiquitination[J]. Cells, 2020, 9(12): 2547. DOI: 10.3390/cells9122547.
[13]	QIAN G, JIN F, CHANG L, et al. NIRF, a novel ubiquitin ligase, interacts with hepatitis B virus core protein and promotes its degradation[J]. Biotechnol Lett, 2012, 34(1): 29-36. DOI: 10.1007/s10529-011-0751-0.
[14]	QIAN G, HU B, ZHOU D, et al. NIRF, a novel ubiquitin ligase, inhibits hepatitis B virus replication through effect on HBV core protein and H3 histones[J]. DNA Cell Biol, 2015, 34(5): 327-332. DOI: 10.1089/dna.2014.2714.
[15]	CHEN JH, YU YS, LIU HH, et al. Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice[J]. Hepat Mon, 2011, 11(8): 620-628. DOI: 10.5812/kowsar.1735143x.689.
[16]	DAI SL, QIU CY, YAO J, et al. Packaging and identification of ubiquitinated HBcAg fusion gene and Tapasin gene expression recombinant lentivirus vectors[J]. China Med Herald, 2019, 16(4): 9-12, 17. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201904003.htm 戴胜兰, 邱彩玉, 姚俊, 等. 重组表达泛素化HBcAg融合基因和Tapasin基因的慢病毒的包装及鉴定[J]. 中国医药导报, 2019, 16(4): 9-12, 17. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201904003.htm
[17]	CHEN JH, YU YS, CHEN XH, et al. Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen[J]. World J Gastroenterol, 2012, 18(12): 1319-1327. DOI: 10.3748/wjg.v18.i12.1319.
[18]	SONG L, ZHUO M, TANG Y, et al. Ubiquitin-modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro[J]. Mol Med Rep, 2015, 12(1): 289-296. DOI: 10.3892/mmr.2015.3352.
[19]	ZHUO M, SONG L, TANG Y, et al. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice[J]. Mol Med Rep, 2015, 12(3): 3591-3598. DOI: 10.3892/mmr.2015.3834.
[20]	SONG L, ZHUO M, TANG Y, et al. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo[J]. Int Immunopharmacol, 2014, 23(1): 1-7. DOI: 10.1016/j.intimp.2014.08.006.
[21]	WANG Y, CUI L, YANG G, et al. Hepatitis B e antigen inhibits NF-κB activity by interrupting K63-linked ubiquitination of NEMO[J]. J Virol, 2019, 93(2): e00667-18. DOI: 10.1128/JVI.00667-18.
[22]	HOU L, ZHAO J, GAO S, et al. Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase[J]. Sci Adv, 2019, 5(2): eaau7130. DOI: 10.1126/sciadv.aau7130.
[23]	LIU X, SHAO J, XIONG W, et al. Cellular cIAP2 gene expression associated with anti-HBV activity of TNF-alpha in hepatoblastoma cells[J]. J Interferon Cytokine Res, 2005, 25(10): 617-626. DOI: 10.1089/jir.2005.25.617.
[24]	WANG Z, NI J, LI J, et al. Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase[J]. J Virol, 2011, 85(21): 11457-11467. DOI: 10.1128/JVI.00879-11.
[25]	MU T, ZHAO X, ZHU Y, et al. The E3 ubiquitin ligase TRIM21 promotes HBV DNA polymerase degradation[J]. Viruses, 2020, 12(3): 346. DOI: 10.3390/v12030346.
[26]	LIU Y, LI J, CHEN J, et al. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways[J]. J Virol, 2015, 89(4): 2287-2300. DOI: 10.1128/JVI.02760-14.
[27]	HU Z, ZHANG Z, DOO E, et al. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex[J]. J Virol, 1999, 73(9): 7231-7240. DOI: 10.1128/JVI.73.9.7231-7240.1999.
[28]	CHEN H, ZHANG Y, YE S, et al. Chromatin remodelling factor BAF155 protects hepatitis B virus X protein (HBx) from ubiquitin-independent proteasomal degradation[J]. Emerg Microbes Infect, 2019, 8(1): 1393-1405. DOI: 10.1080/22221751.2019.1666661.
[29]	ZHANG JF, XIONG HL, CAO JL, et al. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway[J]. Theranostics, 2018, 8(2): 549-562. DOI: 10.7150/thno.20047.
[30]	ZHAO J, WU J, CAI H, et al. E3 ubiquitin ligase Siah-1 is down-regulated and fails to target natural HBx truncates for degradation in hepatocellular carcinoma[J]. J Cancer, 2016, 7(4): 418-426. DOI: 10.7150/jca.13019.
[31]	YEOM S, KIM SS, JEONG H, et al. Hepatitis B virus X protein activates E3 ubiquitin ligase Siah-1 to control virus propagation via a negative feedback loop[J]. J Gen Virol, 2017, 98(7): 1774-1784. DOI: 10.1099/jgv.0.000856.
[32]	YOO YS, PARK YJ, LEE HS, et al. Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis[J]. Cell Death Dis, 2019, 10(12): 938. DOI: 10.1038/s41419-019-2175-z.
[33]	ZHANG H, HUANG C, WANG Y, et al. Hepatitis B virus X protein sensitizes TRAIL-induced hepatocyte apoptosis by inhibiting the E3 ubiquitin ligase A20[J]. PLoS One, 2015, 10(5): e0127329. DOI: 10.1371/journal.pone.0127329.
[34]	MOLINA-JIMÉNEZ F, BENEDICTO I, MURATA M, et al. Expression of pituitary tumor-transforming gene 1 (PTTG1)/securin in hepatitis B virus (HBV)-associated liver diseases: Evidence for an HBV X protein-mediated inhibition of PTTG1 ubiquitination and degradation[J]. Hepatology, 2010, 51(3): 777-787. DOI: 10.1002/hep.23468.
[35]	LEE S, KIM W, KO C, et al. Hepatitis B virus X protein enhances Myc stability by inhibiting SCF(Skp2) ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis[J]. Oncogene, 2016, 35(14): 1857-1867. DOI: 10.1038/onc.2015.251.
[36]	GUO L, WANG X, REN L, et al. HBx affects CUL4-DDB1 function in both positive and negative manners[J]. Biochem Biophys Res Commun, 2014, 450(4): 1492-1497. DOI: 10.1016/j.bbrc.2014.07.019.
[37]	JIANG J, TANG H. Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein[J]. Protein Cell, 2010, 1(12): 1106-1117. DOI: 10.1007/s13238-010-0141-8.
[38]	WEI C, NI C, SONG T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein[J]. J Immunol, 2010, 185(2): 1158-1168. DOI: 10.4049/jimmunol.0903874.
[39]	KONG F, YOU H, KONG D, et al. The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis[J]. Virol J, 2019, 16(1): 73. DOI: 10.1186/s12985-019-1183-z.
[40]	CHEN J, WU M, LIU K, et al. New insights into hepatitis B virus biology and implications for novel antiviral strategies[J]. National Science Review, 2015, 2(4): 296-313. DOI: 10.1093/nsr/nwv044.
[41]	ZHOU L, REN JH, CHENG ST, et al. A functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis B virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A[J]. Hepatology, 2019, 69(5): 1885-1902. DOI: 10.1002/hep.30497.
[42]	WANG Z, KAWAGUCHI K, HONDA M, et al. Notch signaling facilitates hepatitis B virus covalently closed circular DNA transcription via cAMP response element-binding protein with E3 ubiquitin ligase-modulation[J]. Sci Rep, 2019, 9(1): 1621. DOI: 10.1038/s41598-018-38139-5.
[43]	CHENG ST, HU JL, REN JH, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx[J]. J Hepatol, 2021, 74(3): 522-534. DOI: 10.1016/j.jhep.2020.09.019.
[44]	DECORSIÈRE A, MUELLER H, van BREUGEL PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J]. Nature, 2016, 531(7594): 386-389. DOI: 10.1038/nature17170.
[45]	MURPHY CM, XU Y, LI F, et al. Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication[J]. Cell Rep, 2016, 16(11): 2846-2854. DOI: 10.1016/j.celrep.2016.08.026.